symkevi
vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cystic fibrosis - Önnur öndunarfæri - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cystic fibrosis - Önnur öndunarfæri - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
sitagliptin sandoz filmuhúðuð tafla 100 mg
sandoz a/s* - sitagliptinum hýdróklóríð - filmuhúðuð tafla - 100 mg
sitagliptin sandoz filmuhúðuð tafla 50 mg
sandoz a/s* - sitagliptinum hýdróklóríð - filmuhúðuð tafla - 50 mg
ezetimib krka tafla 10 mg
krka d.d. novo mesto* - ezetimibe - tafla - 10 mg
sitagliptin teva filmuhúðuð tafla 25 mg
teva b.v.* - sitagliptinum malat - filmuhúðuð tafla - 25 mg
sitagliptin teva filmuhúðuð tafla 100 mg
teva b.v.* - sitagliptinum malat - filmuhúðuð tafla - 100 mg
sitagliptin teva filmuhúðuð tafla 50 mg
teva b.v.* - sitagliptinum malat - filmuhúðuð tafla - 50 mg
onglyza
astrazeneca ab - saxagliptin - sykursýki, tegund 2 - lyf notuð við sykursýki - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
lokelma
astrazeneca ab - járn sirkon cyclosilicate - blóðkalíumlækkun - Öll önnur lækningavörur - lokelma er ætlað fyrir meðferð hyperkalaemia í fullorðinn sjúklingar.